Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adicet Bio Inc (ACET)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ACET (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -28.96% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.65M USD | Price to earnings Ratio - | 1Y Target Price 6.4 |
Price to earnings Ratio - | 1Y Target Price 6.4 | ||
Volume (30-day avg) 413459 | Beta 1.62 | 52 Weeks Range 0.74 - 2.43 | Updated Date 03/30/2025 |
52 Weeks Range 0.74 - 2.43 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.355 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.31% | Return on Equity (TTM) -65.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -90423291 | Price to Sales(TTM) 9.72 |
Enterprise Value -90423291 | Price to Sales(TTM) 9.72 | ||
Enterprise Value to Revenue 2.14 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 82685800 | Shares Floating 61366056 |
Shares Outstanding 82685800 | Shares Floating 61366056 | ||
Percent Insiders 2.74 | Percent Institutions 69.3 |
Analyst Ratings
Rating 4.43 | Target Price 6.4 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adicet Bio Inc
Company Overview
History and Background
Adicet Bio, Inc. is a biotechnology company founded in 2015. It focuses on the development of allogeneic gamma delta T cell therapies for cancer. The company's goal is to develop off-the-shelf cell therapies that can target a broad range of tumors.
Core Business Areas
- Allogeneic Gamma Delta T Cell Therapies: Adicet Bio develops allogeneic gamma delta T cell therapies for cancer treatment. This involves engineering immune cells to target and kill cancer cells.
- CAR-T Cell Therapy Development: Adicet Bio is involved in the development of CAR-T cell therapies, which involve modifying T cells to express a chimeric antigen receptor (CAR) that targets specific cancer cells.
Leadership and Structure
The leadership team includes Chen Schor, President and CEO. The company operates with a structure typical of a biotechnology firm, with departments dedicated to research, development, manufacturing, and clinical operations.
Top Products and Market Share
Key Offerings
- ADI-001: ADI-001 is an allogeneic gamma delta T cell therapy targeting CD20 for the treatment of relapsed or refractory B-cell lymphomas. Currently in clinical trials. Competitors include companies developing other CAR-T therapies for B-cell lymphomas, such as Novartis (Kymriah) and Gilead Sciences (Yescarta).
- ADI-002: ADI-002 is another allogeneic gamma delta T cell therapy in development. The target and specific clinical application are currently under development and not yet public knowledge, competing with early stage cancer therapies.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with a focus on developing innovative therapies for various diseases, including cancer. The cell therapy market is experiencing significant growth due to the potential of these therapies to provide durable remissions in cancer patients.
Positioning
Adicet Bio is positioned as an innovator in the allogeneic gamma delta T cell therapy field. Its competitive advantage lies in its ability to engineer immune cells to target a broad range of tumors, with the potential for off-the-shelf availability.
Total Addressable Market (TAM)
The total addressable market (TAM) for cell therapies in oncology is estimated to reach billions of dollars. Adicet Bio is positioned to capture a portion of this TAM through the development of its allogeneic gamma delta T cell therapies.
Upturn SWOT Analysis
Strengths
- Novel allogeneic gamma delta T cell platform
- Experienced management team
- Strong intellectual property portfolio
- Clinical trial progress
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on clinical trial success
- Potential for manufacturing challenges
Opportunities
- Expanding clinical trials to new indications
- Partnering with larger pharmaceutical companies
- Advancements in cell therapy manufacturing technologies
- Positive clinical trial data leading to regulatory approval
Threats
- Competition from other cell therapy companies
- Regulatory hurdles and approval timelines
- Clinical trial failures
- Manufacturing issues and scalability challenges
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
Adicet Bio competes with other cell therapy companies, including those developing CAR-T cell therapies and other immunotherapies. Its competitive advantage lies in its allogeneic gamma delta T cell platform, which has the potential for off-the-shelf availability and targeting a broad range of tumors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Adicet Bio's historical growth has been driven by its progress in developing its allogeneic gamma delta T cell therapy platform and advancing its clinical programs.
Future Projections: Future growth is dependent on the success of its clinical trials and regulatory approvals. Analyst estimates suggest potential for significant revenue growth if its therapies are approved.
Recent Initiatives: Recent initiatives include expanding clinical trials to new indications and partnering with larger pharmaceutical companies.
Summary
Adicet Bio is a biotech company with a novel allogeneic gamma delta T cell platform for cancer therapy. The company is in early clinical stages which is a high risk high reward game, requiring it to continue to advance its clinical trials and gain regulatory approval. Adicet Bio faces competition, regulatory hurdles, and financial risks, including clinical trial failures. Adicet Bio's success depends on its ability to execute its clinical development plan and secure partnerships or further funding.
Similar Companies
- GILD
- NVS
- BMY
- BLUE
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and analyst estimates, which are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adicet Bio Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-26 | CEO, President & Director Mr. Chen Schor BA, CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://www.adicetbio.com |
Full time employees 152 | Website https://www.adicetbio.com | ||
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.